NASDAQ: CAPR - Capricor Therapeutics, Inc.

Rentabilität für sechs Monate: +198.31%
Sektor: Healthcare

Aktionsplan Capricor Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

weitere details
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2007-02-13
ISIN US14070B3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.capricor.com
Цена ао 4.19
Preisänderung pro Tag: 0% (14.08)
Preisänderung pro Woche: +7.73% (13.07)
Preisänderung pro Monat: -26.05% (19.04)
Preisänderung über 3 Monate: +41.51% (9.95)
Preisänderung über sechs Monate: +198.31% (4.72)
Preisänderung pro Jahr: +187.93% (4.89)
Preisänderung über 3 Jahre: +335.91% (3.23)
Preisänderung über 5 Jahre: +665.22% (1.84)
Preisänderung über 10 Jahre: 0% (14.08)
Preisänderung seit Jahresbeginn: -6.63% (15.08)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 4.73 3
P/BV 5.27 2
P/E 0 0
EV/EBITDA -4.78 0
Gesamt: 4.38

Effizienz

Name Bedeutung Grad
ROA, % -37.95 0
ROE, % -98.61 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.2439 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 2417.81 10
Rentabilität Ebitda, % 194.99 10
Rentabilität EPS, % -58.18 0
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 1165404 3.7
Woodline Partners LP 909542 2.89
Blackrock Inc. 359673 1.14
Geode Capital Management, LLC 316198 1
Susquehanna International Group, LLP 149115 0.47
Renaissance Technologies, LLC 146321 0.46
Northern Trust Corporation 127229 0.4
Osaic Holdings Inc 116550 0.37
State Street Corporation 85224 0.27
Bank Of New York Mellon Corporation 84759 0.27

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Neuroscience and Healthcare ETF 0.2793 19.72 0.03
iShares Micro-Cap ETF 0.03249 13.79 1.54048
Vanguard Russell 2000 Growth ETF 0.01 17.39 0.60264
iShares Russell 2000 Growth ETF 0.00807 38.04 0.6026
ProShares UltraPro Russell2000 0.00277 89.82 1.47873
ProShares Hedge Replication ETF 0.0008 5.92 1.47892
Vanguard Russell 2000 ETF 0 14.37 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (69 Jahre)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (62 Jahr)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (39 Jahre)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (72 Jahr)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

Adresse: United States, San Diego. CA, 10865 Road to the Cure - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.capricor.com